Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;45(5):1191-1201.
doi: 10.1007/s11064-020-03002-5. Epub 2020 Mar 4.

Monoaminergic and Kynurenergic Characterization of Frontotemporal Dementia and Amyotrophic Lateral Sclerosis in Cerebrospinal Fluid and Serum

Jana Janssens  1   2 , Yannick Vermeiren  1   2 , Martijn van Faassen  3 , Claude van der Ley  3 , Ido P Kema  3 , Peter P De Deyn  4   5   6
Affiliations

Monoaminergic and Kynurenergic Characterization of Frontotemporal Dementia and Amyotrophic Lateral Sclerosis in Cerebrospinal Fluid and Serum

Jana Janssens et al. Neurochem Res. 2020 May.

Abstract

Exploring the neurochemical continuum between frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) with respect to monoamines and kynurenines in cerebrospinal fluid (CSF) and serum, may be useful to identify possible new research/therapeutic targets. Hence, we analysed monoamines and kynurenines in CSF and serum derived from patients with FTD (n = 39), ALS (n = 23), FTD-ALS (n = 4) and age-matched control subjects (n = 26), using reversed-phase ultra-high performance liquid chromatography (RP-UHPLC) with electrochemical detection (ECD) and liquid chromatography tandem mass spectrometry, respectively. We noted a shared dopaminergic disturbance in FTD and ALS when compared to CONTR, with significantly increased serum DA levels and decreased DOPAC concentrations, as well as decreased DOPAC/DA ratios in both disease groups. In CSF, significantly reduced DOPAC concentrations in FTD and ALS were observed as well. Here, a significant increase in DA levels and decrease in DOPAC/DA ratios was only found in FTD relative to CONTR. With respect to the kynurenine pathway (KP), we only found decreased HK/XA ratios, indicative for vitamin B6 status, in serum of ALS subjects compared to FTD. The dopaminergic commonalities observed in FTD and ALS might relate to a disturbance of dopaminergic nerve terminals in projection areas of the substantia nigra and/or ventral tegmental area, although these findings should first be confirmed in brain tissue. Lastly, based on the results of this work, the KP does not hold promise as a research/therapeutic target in FTD and ALS.

Keywords: Biomarker; Dementia; Neuropathology; Neurophysiology.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflict of interest.

Figures

Fig. 1
Fig. 1
Overview of neuropathological diagnoses in the FTD group. C9ORF72 chromosome 9 open reading frame 72, FTLD-U frontotemporal lobar degeneration with ubiquitin-positive inclusions, FTD frontotemporal dementia, GRN progranulin gene, TBK1 TANK-binding kinase 1, TDP-43 transactive response DNA-binding protein of 43 kDa, VCP valosin-containing protein
Fig. 2
Fig. 2
Dopaminergic findings across diagnostic categories. Data are represented as box- and whisker plots with minimum–maximum ranges. Statistically significant differences after Mann–Whitney U tests with Benjamini–Hochberg post-hoc corrections are depicted by one, two or three asterisks if P ≤ 0.05, 0.001, or 0.0001, respectively. Sample sizes for CSF DOPAC are: CONTR: n = 26, FTD: n = 39, FTD-ALS: n = 4, ALS: n = 23, sample sizes for CSF DA and DOPAC/DA are CONTR: n = 21, FTD: n = 35, FTD-ALS: n = 2, ALS: n = 17. Sample sizes for serum DOPAC are: CONTR: n = 26, FTD: n = 39, FTD-ALS: n = 3, ALS: n = 20, sample sizes for serum DA and DOPAC/DA are: CONTR: n = 26, FTD: n = 35, FTD-ALS: n = 3, ALS: n = 20. The FTD-ALS group was not included in the statistical analysis. ALS amyotrophic lateral sclerosis, CONTR control, CSF cerebrospinal fluid, DA dopamine, DOPAC 3,4-dihydroxyphenylacetic acid, FTD frontotemporal dementia, FTD-ALS frontotemporal dementia—amyotrophic lateral sclerosis
Fig. 3
Fig. 3
CSF HVA/DA ratios across diagnostic categories. Data are represented as box- and whisker plots with minimum–maximum ranges. Statistically significant differences after Mann–Whitney U analyses with Benjamini–Hochberg corrections are indicated by an asterisk (P < 0.05). Sample sizes for CSF HVA/DA are: CONTR: n = 21, FTD: n = 35, FTD-ALS: n = 2, ALS: n = 17. The FTD-ALS group was not included in the statistical analysis. ALS amyotrophic lateral sclerosis, CONTR control, CSF cerebrospinal fluid, DA dopamine, FTD frontotemporal dementia, FTD-ALS frontotemporal dementia-amyotrophic lateral sclerosis, HVA homovanillic acid
Fig. 4
Fig. 4
CSF MHPG levels across diagnostic categories. Data are represented as box- and whisker plots with minimum–maximum ranges. Statistically significant differences after Mann–Whitney U analyses with Benjamini–Hochberg corrections are indicated by an asterisk (P < 0.05). Sample sizes for CSF MHPG are: CONTR: n = 26, FTD = 39, FTD-ALS: n = 4, ALS: n = 23. The FTD-ALS group was not included in the statistical analysis. ALS amyotrophic lateral sclerosis, CONTR control, CSF cerebrospinal fluid, FTD frontotemporal dementia, FTD-ALS frontotemporal dementia-amyotrophic lateral sclerosis, MHPG 3-methoxy-4-hydroxyphenylglycol
Fig. 5
Fig. 5
The KP in CSF. Data are represented as box- and whisker plots with minimum–maximum ranges. Statistically significant differences after Mann–Whitney U analyses with Benjamini–Hochberg corrections are indicated by an asterisk (P < 0.05). Sample sizes for TRP are: CONTR: n = 23, FTD: n = 37, FTD-ALS: n = 4, ALS: n = 20, sample sizes for KYN are: CONTR: n = 21, FTD: n = 37, FTD-ALS: n = 4, ALS: n = 21, sample sizes for HK are: CONTR: n = 24, FTD: n = 36, FTD-ALS: n = 4, ALS: n = 21, sample sizes for KA are: CONTR: n = 25, FTD: n = 39, FTD-ALS: n = 4, ALS: n = 22, sample sizes for AA are: CONTR: n = 24, FTD: n = 39, FTD-ALS: n = 4, ALS: n = 22, sample sizes for XA are: CONTR: n = 17, FTD: n = 30, FTD-ALS: n = 3, ALS: n = 18, sample sizes for QA are: CONTR: n = 23, FTD: n = 37, FTD-ALS: n = 4, ALS: n = 21, sample sizes for PA are: CONTR: n = 24, FTD: n = 39, FTD-ALS: n = 4, ALS: n = 22, sample sizes for NA are: CONTR: n = 25, FTD: n = 39, FTD-ALS: n = 4, ALS: n = 22, sample sizes for KYN/TRP are: CONTR: n = 21, FTD: n = 35, FTD-ALS: n = 4, ALS: n = 20, sample sizes for HK/XA are: CONTR: n = 15, FTD: n = 30, FTD-ALS: n = 3, ALS: n = 18. AA anthranilic acid; ALS amyotrophic lateral sclerosis, CONTR control, CSF cerebrospinal fluid, FTD frontotemporal dementia, FTD-ALS frontotemporal dementia-amyotrophic lateral sclerosis, HK 3-hydroxykynurenine, KA kynurenic acid, KP kynurenine pathway, KYNl-kynurenine, NA nicotinic acid, PA picolinic acid, QA quinolinic acid, TRPl-tryptophan, XA xanthurenic acid
Fig. 6
Fig. 6
The KP in serum. Data are represented as box- and whisker plots with minimum–maximum ranges. Statistically significant differences after Mann–Whitney U analyses with Benjamini–Hochberg corrections are indicated by an asterisk (P < 0.05). Sample sizes for TRP are: CONTR: n = 26, FTD: n = 39, FTD-ALS: n = 3, ALS: n = 20, sample sizes for KYN are: CONTR: n = 26, FTD: n = 39, FTD-ALS: n = 3, ALS: n = 20, sample sizes for HK are: CONTR: n = 24, FTD: n = 39, FTD-ALS: n = 3, ALS: n = 19, sample sizes for KA are: CONTR: n = 26, FTD: n = 39, FTD-ALS: n = 3, ALS: n = 20, sample sizes for AA are: CONTR: n = 26, FTD: n = 38, FTD-ALS: n = 3, ALS: n = 20, sample sizes for XA are: CONTR: n = 25, FTD: n = 39, FTD-ALS: n = 3, ALS: n = 20, sample sizes for QA are: CONTR: n = 25, FTD: n = 37, FTD-ALS: n = 3, ALS: n = 18, sample sizes for PA are: CONTR: n = 25, FTD: n = 39, FTD-ALS: n = 3, ALS: n = 20, sample sizes for NA are: CONTR: n = 24, FTD: n = 38, FTD-ALS: n = 3, ALS: n = 20, sample sizes for KYN/TRP are: CONTR: n = 26, FTD: n = 39, FTD-ALS: n = 3, ALS: n = 19, sample sizes for HK/XA are: CONTR: n = 22, FTD: n = 38, FTD-ALS: n = 3, ALS: n = 18
See this image and copyright information in PMC

References

    1. Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, Chio A, Restagno G, Nicolaou N, Simon-Sanchez J, van Swieten JC, Abramzon Y, Johnson JO, Sendtner M, Pamphlett R, Orrell RW, Mead S, Sidle KC, Houlden H, Rohrer JD, Morrison KE, Pall H, Talbot K, Ansorge O, Chromosome ALSFTDC, French Research Network on FFA, Consortium I. Hernandez DG, Arepalli S, Sabatelli M, Mora G, Corbo M, Giannini F, Calvo A, Englund E, Borghero G, Floris GL, Remes AM, Laaksovirta H, McCluskey L, Trojanowski JQ, Van Deerlin VM, Schellenberg GD, Nalls MA, Drory VE, Lu CS, Yeh TH, Ishiura H, Takahashi Y, Tsuji S, Le Ber I, Brice A, Drepper C, Williams N, Kirby J, Shaw P, Hardy J, Tienari PJ, Heutink P, Morris HR, Pickering-Brown S, Traynor BJ. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol. 2012;11(4):323–330. doi: 10.1016/S1474-4422(12)70043-1. - DOI - PMC - PubMed
    1. Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC, Laaksovirta H, van Swieten JC, Myllykangas L, Kalimo H, Paetau A, Abramzon Y, Remes AM, Kaganovich A, Scholz SW, Duckworth J, Ding J, Harmer DW, Hernandez DG, Johnson JO, Mok K, Ryten M, Trabzuni D, Guerreiro RJ, Orrell RW, Neal J, Murray A, Pearson J, Jansen IE, Sondervan D, Seelaar H, Blake D, Young K, Halliwell N, Callister JB, Toulson G, Richardson A, Gerhard A, Snowden J, Mann D, Neary D, Nalls MA, Peuralinna T, Jansson L, Isoviita VM, Kaivorinne AL, Holtta-Vuori M, Ikonen E, Sulkava R, Benatar M, Wuu J, Chio A, Restagno G, Borghero G, Sabatelli M, Consortium I. Heckerman D, Rogaeva E, Zinman L, Rothstein JD, Sendtner M, Drepper C, Eichler EE, Alkan C, Abdullaev Z, Pack SD, Dutra A, Pak E, Hardy J, Singleton A, Williams NM, Heutink P, Pickering-Brown S, Morris HR, Tienari PJ, Traynor BJ. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257–268. doi: 10.1016/j.neuron.2011.09.010. - DOI - PMC - PubMed
    1. Van Langenhove T, van der Zee J, Gijselinck I, Engelborghs S, Vandenberghe R, Vandenbulcke M, De Bleecker J, Sieben A, Versijpt J, Ivanoiu A, Deryck O, Willems C, Dillen L, Philtjens S, Maes G, Baumer V, Van Den Broeck M, Mattheijssens M, Peeters K, Martin JJ, Michotte A, Santens P, De Jonghe P, Cras P, De Deyn PP, Cruts M, Van Broeckhoven C. Distinct clinical characteristics of C9orf72 expansion carriers compared with GRN, MAPT, and nonmutation carriers in a Flanders-Belgian FTLD cohort. JAMA Neurol. 2013;70(3):365–373. doi: 10.1001/2013.jamaneurol.181. - DOI - PubMed
    1. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602–611. doi: 10.1016/j.bbrc.2006.10.093. - DOI - PubMed
    1. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VMY. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130–133. doi: 10.1126/science.1134108. - DOI - PubMed

MeSH terms